Phase I & II (a-b-c) Clinical Trials involved intravenous infusion secessions lasting up to 4 hours once a week, for several weeks.
Our IP places nano PGE-1 particles into multi-lamellar liposomes for controlled drug release. We currenctly get hours and have provisional IP that should provide days of PGI-1 exposure.
The longer PGE-1 stays in the circulatory system, the better the effects on controlling inflammation, clotting, vasodilation, and promotion of capillary growth.
The normal half life of PGE-1 is measured in minutes, which is not enough time for the drug to be effective. Hours and days are needed to optimize the effectivenes of PGE-1.